Want to see SE:SPEC full AI Analyst Report?
Top Page
SpectraCure AB
(SPEC)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.04
▼(-75.56% Downside)
Action:Reiterated
Date:06/16/26
The score is primarily driven down by weak financial performance (negligible revenue, sizable losses, and sustained cash burn), partially offset by low leverage. Technicals add pressure given the strong downtrend, and valuation is constrained by negative earnings and no dividend yield.
Positive Factors
Low Leverage / Balance Sheet Flexibility
Very low debt-to-equity (~0.03) materially reduces near-term solvency risk and gives management durable optionality to fund development programs or secure bridge financing on better terms, supporting continuation of clinical development without immediate liquidity distress.
Negative Factors
Negligible Revenue and Large Losses
The company has no meaningful commercial revenue and sustained large net losses (~-56m), indicating the business is not yet at a commercial run-rate. Long-term viability depends on successful clinical progress or financing, leaving outcomes tied to execution of development milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet Flexibility
Very low debt-to-equity (~0.03) materially reduces near-term solvency risk and gives management durable optionality to fund development programs or secure bridge financing on better terms, supporting continuation of clinical development without immediate liquidity distress.
Read all positive factors
SpectraCure AB (SPEC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr31.38M
Dividend YieldN/A
Average Volume (3M)1.15M
Price to Earnings (P/E)―
Beta (1Y)-0.30
Revenue GrowthN/A
EPS Growth-85.81%
CountrySE
Employees16
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.19
Shares Outstanding570,602,840
10 Day Avg. Volume1,242,664
30 Day Avg. Volume1,152,681
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-1.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SpectraCure AB Business Overview & Revenue Model
Company Description
SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT)...
How the Company Makes Money
null...
SpectraCure AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 318.00K | 539.00K | 0.00 |
| Gross Profit | -27.03M | -30.14M | 9.77M | -9.22M | 3.58M | 1.39M |
| EBITDA | -24.81M | -24.22M | -20.42M | -20.97M | -22.27M | -20.43M |
| Net Income | -55.90M | -56.08M | -23.00M | -20.44M | -25.33M | -23.34M |
Balance Sheet | ||||||
| Total Assets | 111.01M | 104.47M | 121.00M | 144.83M | 162.42M | 190.52M |
| Cash, Cash Equivalents and Short-Term Investments | 16.59M | 13.53M | 18.27M | 56.95M | 93.18M | 129.69M |
| Total Debt | 2.19M | 3.01M | 5.14M | 6.72M | 2.70M | 4.90M |
| Total Liabilities | 10.60M | 10.92M | 14.15M | 14.97M | 12.12M | 14.84M |
| Stockholders Equity | 100.41M | 93.55M | 106.86M | 129.86M | 150.30M | 175.68M |
Cash Flow | ||||||
| Free Cash Flow | -28.61M | -43.67M | -37.10M | -34.45M | -33.08M | -27.09M |
| Operating Cash Flow | -23.75M | -24.03M | -21.83M | -18.68M | -22.96M | -18.60M |
| Investing Cash Flow | -20.22M | -19.64M | -15.28M | -15.56M | -11.35M | -8.49M |
| Financing Cash Flow | 52.47M | 38.92M | -1.57M | -1.99M | -2.20M | -453.00K |
SpectraCure AB Technical Analysis
Negative
0.18
Price Trends
0.08
Negative
0.09
Negative
0.13
Negative
Market Momentum
-0.02
Positive
30.36
Neutral
12.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPEC, the sentiment is Negative. The current price of 0.18 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.08, and above the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 30.36 is Neutral, neither overbought nor oversold. The STOCH value of 12.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPEC.
SpectraCure AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr187.80M | -1.91 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | kr45.61M | -13.27 | ― | ― | -12.32% | -1156.14% | |
44 Neutral | kr332.32M | -1.55 | -253.54% | ― | 41.17% | 29.20% | |
43 Neutral | kr30.98M | -0.72 | -60.56% | ― | 27.31% | 6.31% | |
42 Neutral | kr31.38M | -0.30 | -50.21% | ― | ― | -85.81% |
* Healthcare Sector Average
SE:SPEC
SpectraCure AB
0.06
-0.18
-76.39%
SE:SCIB
SciBase Holding AB
32.50
1.58
5.12%
SE:LXB
Luxbright AB
0.12
-0.58
-82.88%
SE:HEART
Scandinavian Real Heart AB
22.10
7.90
55.64%
SE:SDOS
ScandiDos AB
0.80
-0.55
-40.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.